To include your compound in the COVID-19 Resource Center, submit it here.

Redwood Bioscience: Tagging ADCs

Redwood Bioscience uses UC Berkeley technology for antibody-drug conjugates

Because the first generation of antibody-drug conjugate technologies result in heterogeneous mixtures of molecules with variable potency and toxicity, several companies are developing methods that provide greater control over where the toxin payloads are attached.

Redwood Bioscience Inc. believes its site-specific aldehyde tagging technology provides the greatest flexibility in the number and location of attachment sites, which should allow it to improve efficacy and optimize dosing.

ADCs consist of a targeting antibody that binds to a receptor on a diseased cell, plus a toxin and a linker.

Read the full 856 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers